Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
In the AlphaLISA SureFire Ultra assay, Donor beads are coated with streptavidin to capture one of the antibodies, which is biotinylated. Acceptor beads are coated with a proprietary CaptSure™ agent that immobilizes the other antibody, labeled with a CaptSure tag. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor beads close together, generating signal. The amount of light emission is directly proportional to the amount of phosphoprotein present in the sample.
AlphaLISA SureFire Ultra kits are compatible with:
Alpha SureFire kits can be used for:
|Assay Target Class||Phosphoprotein|
|Product Brand Name||AlphaLISA SureFire Ultra|
|Quantity in a Package Amount||500.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Central Nervous System, Cardiovascular, Metabolic|
|Unit Size||500 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
In this application note, we demonstrate an efficient cell-based workflow for the assessment of EGF treatment effects in a cellular model of human skin cancer.
Treatment effects on several intracellular signaling pathways were examined using PerkinElmer’s homogeneous, no-wash AlphaLISA® SureFire® Ultra assays. To determine concurrent time-dependent effects of different EGF concentrations on cellular health and proliferation, ATP concentrations were assessed with ATPlite™ 1step luminescence assay and cultures were fluorescently labeled, imaged and analyzed using the Operetta CLS™ high-content analysis system.
G protein coupled-receptors (GPCRs) are one of the most intensively studied drug targets, with up to one-third of all marketed therapeutics acting by binding to GPCRs. Therapies that target GPCRs include both agonist and antagonists that are used in the treatment of disease in nearly every major organ system and hold significance in several therapeutic areas, such as cardiovascular diseases, neurosciences, respiratory diseases, metabolic disorders, oncology, and rare diseases.
We know the importance of furthering GPCR research - and we answer the call with application notes, white papers, and end-to-end solutions including reagents, instruments, and tools for all aspects of research into today’s most promising drug target.